The estimated Net Worth of Nicole Murphy is at least $1.94 million dollars as of 1 April 2024. Ms Murphy owns over 240 units of Biogen Inc stock worth over $1,941,327 and over the last 3 years she sold BIIB stock worth over $0.
Ms has made over 12 trades of the Biogen Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 240 units of BIIB stock worth $47,782 on 1 April 2024.
The largest trade she's ever made was exercising 2,611 units of Biogen Inc stock on 10 February 2023 worth over $519,824. On average, Ms trades about 705 units every 49 days since 2022. As of 1 April 2024 she still owns at least 9,751 units of Biogen Inc stock.
You can see the complete history of Ms Murphy stock trades at the bottom of the page.
Nicole Murphy is the Head of Pharmaceutical Operations & Technology at Biogen Inc.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner et Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: